On September 19, 2019 NexImmune and the Multiple Myeloma Research Foundation (MMRF) reported that they have entered into a partnership to advance a promising new therapy into clinical trials for multiple myeloma patients (Press release, NexImmune, SEP 19, 2019, View Source [SID1234554877]). The Neximmune team was invited to the offices of MMRF to discuss a broad range of collaborative opportunities that focus on advancing the health of patients diagnosed with Multiple Myeloma. The MMRF’s newly formed Myeloma Investment Fund (MIF) mission is to support promising companies and technologies by accelerating the clinical development of innovative therapies with potential to benefit myeloma patients. The MIF has made an equity investment in NexImmune to help support the initial clinical development of NEXI-002 for patients with relapsed / refractory Multiple Myeloma, and to further help develop the Company’s Artificial Immune Modulatory (AIM) technology platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!